RISK FACTORS FOR VIRAL INFECTIONS FOLLOWING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE IN PATIENTS WITH VARIOUS HEMATOLOGIC DISORDERS: A SINGLE CENTER EXPERIENCE
Haploidentical hematopoietic stem cell transplantation (haplo-HCT) with post-transplant cyclophosphamide (PTCy) increases the donor pool for allogeneic HCT but is associated with significant early viral reactivation. Current factors implicated in viral reactivation following haplo-HCT include: T-cell depletion (in-vivo or ex-vivo), use of PTCy, human leukocyte antigen (HLA) disparity, and grades II-IV acute GVHD. The incidence of cumulative viral reactivation following haplo-HCT using bone marrow (BM) has been reported as 77% at 1-year (CMV 54%, EBV 37% and BK cystitis 19%) in at risk patients. However, limited data exists on viral reactivation rates based on a peripheral blood stem cell (PBSC) source. We hypothesized that haplo-HCT with PTCy using PBSC will mitigate early viral reactivation as compared to BM.